The T-SPOT®.TB test is a unique, single-visit blood test, also known as an interferon-gamma release assay (IGRA) for TB infection. The T-SPOT.TB test is the only blood test that has demonstrated in a pivotal clinical study both sensitivity and specificity exceeding 95% and reliability in all at-risk groups.1 The T-SPOT.TB test does not cross react with the bacille Calmette-Guerin (BCG) vaccine and there is no association between
T-SPOT.TB test results and immunocompromised status.

On 23rd March 2011, the National Institute of Health and Clinical Excellence (NICE) issued new guidelines recommending the use of Interferon Gamma Release Assays (IGRAs) for the detection of tuberculosis in a number of important patient groups2.

The new release was specifically designed to update IGRA guidance in light of new evidence that has emerged on IGRAs since the last issue in 2006. IGRAs are recommended to replace the TST in the following situations:

  • In BCG vaccinated persons
  • In an outbreak situation when large numbers of individuals are screened
  • In recent arrivals from high incidence countries aged 16 to 34 years old
  • In immunocompromised adults
  • In new NHS employees from high incidence countries (>40:100,000)
  • In new NHS employees who have had contact with patients in a setting where TB is highly prevalent
  • In hard to reach populations

In addition, IGRAs should also be used to confirm TST positives.

To learn more about the advantages of the T-SPOT.TB test, click here.


1T-SPOT.TB Package Insert.
2NICE Clinical Guideline 117. ‘Tuberculosis’. March 2011.

Oxford Diagnostic Laboratories
are a Trading Division of Oxford Immunotec Ltd.

U.S. Headquarters | Int'l Headquarters

Labs Conducting the T-SPOT.TB Test

Innovative Products and Solutions